Gemcitabine-loaded synthetic high-density lipoprotein preferentially eradicates hepatic monocyte-derived macrophages in mouse liver with colorectal cancer metastases

Acta Pharmacol Sin. 2023 Nov;44(11):2331-2341. doi: 10.1038/s41401-023-01110-w. Epub 2023 May 24.

Abstract

Liver metastasis of colorectal cancer (CRC) is the critical cause of CRC-related death due to its unique immunosuppressive microenvironment. In this study we generated a gemcitabine-loaded synthetic high-density lipoprotein (G-sHDL) to reverse immunosuppression in livers with CRC metastases. After intravenous injection, sHDL targeted hepatic monocyte-derived alternatively activated macrophages (Mono-M2) in the livers of mice bearing both subcutaneous tumors and liver metastases. The G-sHDL preferentially eradicated Mono-M2 in the livers with CRC metastases, which consequently prevented Mono-M2-mediated killing of tumor antigen-specific CD8+ T cells in the livers and thus improved the densities of tumor antigen-specific CD8+ T cells in the blood, tumor-draining lymph nodes and subcutaneous tumors of the treated mice. While reversing the immunosuppressive microenvironment, G-sHDL also induced immunogenic cell death of cancer cells, promoted maturation of dendritic cells, and increased tumor infiltration and activity of CD8+ T cells. Collectively, G-sHDL inhibited the growth of both subcutaneous tumors and liver metastases, and prolonged the survival of animals, which could be further improved when used in conjunction with anti-PD-L1 antibody. This platform can be a generalizable platform to modulate immune microenvironment of diseased livers.

Keywords: colorectal cancer; gemcitabine; liver metastasis; macrophages; synthetic high-density lipoprotein.

MeSH terms

  • Animals
  • Antigens, Neoplasm
  • CD8-Positive T-Lymphocytes / metabolism
  • Cell Line, Tumor
  • Colorectal Neoplasms* / drug therapy
  • Gemcitabine
  • Lipoproteins, HDL
  • Liver Neoplasms* / drug therapy
  • Liver Neoplasms* / metabolism
  • Macrophages / metabolism
  • Mice
  • Tumor Microenvironment

Substances

  • Gemcitabine
  • Lipoproteins, HDL
  • Antigens, Neoplasm